BIOFRONTERA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 USD | -5.92% |
|
-5.92% | -42.60% |
| 18/03 | Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024 | |
| 15/03 | Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 40.7M 3.39B | Sales 2025 * | 49.94M 4.16B | Capitalization | 8.09M 674M |
|---|---|---|---|---|---|
| Net income 2024 * | -16M -1.33B | Net income 2025 * | -3M -250M | EV / Sales 2024 * | 0.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.16 x |
| P/E ratio 2024 * |
-0.49
x | P/E ratio 2025 * |
-2.92
x | Employees | 84 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biofrontera Inc.
More recommendations
More press releases
| 1 day | -5.92% | ||
| 1 week | -5.92% | ||
| Current month | +3.25% | ||
| 1 month | +3.25% | ||
| 3 months | +5.30% | ||
| 6 months | -56.44% | ||
| Current year | -42.60% |
1 week
1.41
1.73
1 month
1.382.43
Current year
0.613.90
1 year
0.6113.42
3 years
0.61292.60
5 years
0.61292.60
10 years
0.61292.60
| Managers | Title | Age | Since |
|---|---|---|---|
Hermann Lübbert
CEO | Chief Executive Officer | 68 | 01/15/01 |
Fred Leffler
DFI | Director of Finance/CFO | 41 | 24/22/24 |
Erica Gates
DFI | Director of Finance/CFO | - | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Borer
BRD | Director/Board Member | 67 | 02/21/02 |
Hermann Lübbert
CEO | Chief Executive Officer | 68 | 01/15/01 |
Kevin D. Weber
BRD | Director/Board Member | 66 | 02/22/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.59 | -5.92% | 50,733 |
| 25/24/25 | 1.69 | +1.81% | 26,034 |
| 24/24/24 | 1.66 | +11.04% | 62,969 |
| 23/24/23 | 1.495 | +3.46% | 54,109 |
| 22/24/22 | 1.445 | -14.50% | 93,931 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Sector
Pharmaceuticals
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.59
USD
Average target price
16
USD
Spread / Average Target
+906.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.60% | 8.09M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BFRI Stock
